AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 284: E1106-E1111, 2003; doi:10.1152/ajpendo.00292.2002
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dallinger, S.
Right arrow Articles by Schmetterer, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dallinger, S.
Right arrow Articles by Schmetterer, L.
Vol. 284, Issue 6, E1106-E1111, June 2003

Vasodilator effects of L-arginine are stereospecific and augmented by insulin in humans

Susanne Dallinger1, Anna Sieder1, Jeanette Strametz1,3, Michaela Bayerle-Eder1, Michael Wolzt1, and Leopold Schmetterer1,2

1 Department of Clinical Pharmacology, 2 Institute of Medical Physics, and 3 Department of Cardiology, University of Vienna, A-1090 Vienna, Austria

The amino acid L-arginine, the precursor of nitric oxide (NO) synthesis, induces vasodilation in vivo, but the mechanism behind this effect is unclear. There is, however, some evidence to assume that the L-arginine membrane transport capacity is dependent on insulin plasma levels. We hypothesized that vasodilator effects of L-arginine may be dependent on insulin plasma levels. Accordingly, we performed two randomized, double-blind crossover studies in healthy male subjects. In protocol 1 (n = 15), subjects received an infusion of insulin (6 mU · kg-1 · min-1 for 120 min) or placebo and, during the last 30 min, L-arginine or D-arginine (1 g/min for 30 min). In protocol 2 (n = 8), subjects received L-arginine in stepwise increasing doses in the presence (1.5 mU · kg-1 · min-1) or absence of insulin. Renal plasma flow and glomerular filtration rate were assessed by the para-aminohippurate and inulin plasma clearance methods, respectively. Pulsatile choroidal blood flow was assessed with laser interferometric measurement of fundus pulsation, and mean flow velocity in the ophthalmic artery was measured with Doppler sonography. L-arginine, but not D-arginine, significantly increased renal and ocular hemodynamic parameters. Coinfusion of L-arginine with insulin caused a dose-dependent leftward shift of the vasodilator effect of L-arginine. This stereospecific renal and ocular vasodilator potency of L-arginine is enhanced by insulin, which may result from facilitated L-arginine membrane transport, enhanced intracellular NO formation, or increased NO bioavailability.

renal plasma flow; ocular blood flow; nitric oxide





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.